Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTCOV: NDV-HXP-S Phase I
NCT04993209Phase 1Completed
- Sponsor
- Instituto Butantan
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Patria in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Instituto Butantan. Primary endpoints: Adverse reactions, Laboratory evaluations and 2 more. Started Jul 2021; status: completed.
02
Drugs
Patria
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04993209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993209.